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The generation of functional hepatocytes is a major challenge for regenerative medicine and drug discovery. Here
we show a method that facilitates generation of induced functional hepatocytes (iHeps) from adipose-derived stem
cells (ADSCs) within 9 days. iHeps express hepatocytic gene programs and display functions characteristic of mature
hepatocytes, including cytochrome P450 enzyme activity. Upon transplantation into mice with carbon tetrachloride
(CCl4)-induced acute fulminant liver failure, iHeps restore the liver function and prolong survival. The work could
contribute to the development of alternative strategies to obtain nonhepatic cell-derived mature hepatocytes with
potential for biomedical and pharmaceutical applications.Introduction
Functional hepatocytes are in high demand in the field
of regenerative medicine and drug development. They
show great potential for repairing or replacing diseased
and damaged tissues and can be valuable tools for
pharmaceutical applications. However, the practical
application of primary hepatocytes has been frustrated
by their tendency to rapidly dedifferentiate and lose
most hepatic functions after growth in a tissue culture
environment [1–4]. To solve this dilemma, novel strat-
egies for generating sufficient hepatocytes are in high
demand. In the last few years, extrahepatic cell popula-
tions with potential to generate functional hepatocytes
have been discovered [5–8]. Currently, attention is being
given to mesenchymal stem cells (MSCs) [9, 10], which
can be obtained from different sources such as bone
marrow [11], amniotic fluid [12], umbilical cord blood
[13], scalp tissue [14], placenta [15], or adipose tissue
[16] of the body. These cells show the ability of* Correspondence: denghongx@scu.edu.cn
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particular, adipose-derived stem cells (ADSCs) are
recognized as one of the most promising MSCs iden-
tified thus far, since adipose tissue is ubiquitous and
easily obtained in large quantities with little donor
site morbidity or discomfort [17–20]. Furthermore,
recent research has revealed that the use of ADSCs
in regenerative medicine is not limited to mesodermal
tissue but extended to both ectodermal and endoder-
mal tissues and organs, although ADSCs originate
from mesodermal lineages [21–25].
In the present study, we describe the generation of
induced functional hepatocytes (iHeps) from rat ADSCs
in a rapid and high-efficiency manner. iHeps express
hepatocytic gene programs and possess the functional
properties of mature hepatocytes, including albumin
(ALB) secretion, urea synthesis, and cytochrome P
(CYP) 450 enzyme activity. Notably, we demonstrate the
therapeutic effects of iHeps on carbon tetrachloride
(CCl4)-induced acute fulminant liver failure. These
results indicate that iHeps could be applied in cellular
therapies, disease modeling, and drug discovery.istributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Isolation, culture, and identification of rat ADSCs
Isolation of ADSCs was performed as described previ-
ously [26] with some modifications. The inguinal fat pad
was collected under sterile conditions from 5-week-old
female Lewis rats (Vital River Laboratory, Chengdu,
Sichuan, P.R. China) and washed with Hank’s balanced
salt solution (HBSS; Gibco, Chengdu, Sichuan, P.R.
China). The washing step was usually repeated three
times. Adipose tissue sample was minced into small pieces
and digested in 0.1 % collagenase type I (3 ml for each 1 g
tissue; Gibco) at 37 °C for 1 hour with a rotation speed of
120 rpm. After digestion, an equal volume of low-glucose
Dulbecco’s modified Eagle’s medium (DMEM-LG; Gibco)
containing 10 % fetal bovine serum (FBS; Gibco) was
added. The cell suspension was filtered through a 100 μm
filter (BD Falcon, Chengdu, Sichuan, P.R. China) for the
removal of the solid aggregates. The sample was sub-
sequently centrifuged at 1500 rpm for 10 minutes at 4 °C
and completed the separation of the stromal cells from
the adipocytes. The centrifugation step was repeated. The
cells were resuspended in complete medium (DMEM-
LG with 10 % FBS, 100 U/ml penicillin, and 100 μg/ml
streptomycin) in a 75 cm2 culture dish and were main-
tained at 37 °C in saturated humidity with 5 % carbon
dioxide. After 1 day, nonadherent cells were removed
by two or three washes with HBBS and medium changes
were performed every 2 days thereafter. Cell morphology
was monitored under an inverted microscope. Passage 3
cells were used for flow cytometry analysis and differenti-
ation assays.
For flow cytometry analysis, 5 × 105 ADSCs (in 100 μl
phosphate-buffered saline (PBS)) were incubated with
different fluorescently labeled monoclonal antibodies
(anti-rat CD45-PECy5, anti-rat CD31-PE, anti-rat CD29-
FITC, anti-rat CD44H-FITC, and anti-rat CD90-FITC;
Biolegend, Chengdu, Sichuan, P.R. China) and incubated
in the dark at 2–8 °C for 30 minutes. After washing
twice with PBS, cells were resuspended in 300 μl PBS
and analyzed by the Calibur flow cytometer (BD Biosci-
ences, Chengdu, Sichuan, P.R. China).
For adipocytic differentiation, ADSCs (5 × 103 cells/cm2)
were seeded in six-well plates. When ~100 % confluent,
cells were maintained in adipocyte genesis medium (PT-
3004; Lonza, Chengdu, Sichuan, P.R. China) for 2 weeks.
Cells were then stained with Oil red O.Table 1 Hepatic lineage differentiation condition
Induction period Medium cont
Endodermal induction Days 0–1 RPMI-1640, ID
Hepatogenic induction Days 2–4 RPMI-1640, ID
Maturation step Days 5–9 Williams’ E, H
DEX dexamethasone, EGF epidermal growth factor, FGF4 fibroblast growth factor 4,
Oncostatin MFor osteogenic differentiation, ADSCs (5 × 103 cells/
cm2) were seeded in six-well plates. When ~100 % conflu-
ent, cells were treated with inducing medium (PT-3002;
Lonza) for 3 weeks. Cells were then fixed with 4 % formal-
dehyde for 30 minutes and stained with Alizarin Red.
For chondrogenic differentiation, ADSCs were seeded
at a density of 106 per well in an ultralow attachment
six-well plate, and cultured with inducing medium
(PT-3003; Lonza) for 3 weeks. Cells were then identi-
fied by Alcian blue staining.In vitro differentiation of ADSCs into iHeps
At passages 3–7, the cells were seeded on collagen type
I-coated culture dishes at a concentration of 2.0 × 104
cells/cm2. When the cells reached 100 % confluence,
hepatic induction was carried out over a period of
9 days (Table 1). First, the cells were treated for 1 day
of endodermal induction with RPMI-1640 (Gibco) sup-
plemented with 100 nM IDE1 (Tocris, Chengdu, Si-
chuan, P.R. China) and 3 μΜ CHIR99021 (Selleckchem,
Chengdu, Sichuan, P.R. China). During the next step,
the culture medium was replaced with hepatogenic in-
duction medium containing 100 nM IDE1, 20 ng/ml
fibroblast growth factor 4 (FGF4; PeproTech, Chengdu,
Sichuan, P.R. China), and 150 ng/ml hepatocyte growth
factor (HGF; PeproTech). Finally, during the matur-
ation step, the cells were cultured in Williams’ E
(Gibco) supplemented with 50 ng/ml HGF, 20 ng/ml
epidermal growth factor (EGF; PeproTech), 30 ng/ml
oncostatin M (OsM; PeproTech), 2 × 10−5 mol/l dexa-
methasone (Dex; Sigma, Chengdu, Sichuan, P.R. China)
and 1 × insulin–transferrin–selenium (ITS; Sigma).Flow cytometry analysis
For intracellular staining of ALB and alpha-1-antitrypsin
(AAT), 5 × 105 iHeps were harvested and fixed with 4 %
paraformaldehyde for 30 minutes, and then permeabilized
in staining buffer (BD Biosciences) for 10 minutes. Cells
were then incubated with primary antibody—sheep anti-
ALB (Bethyl, Chengdu, Sichuan, P.R. China) and rabbit
anti-AAT (American Research Products, Chengdu,
Sichuan, P.R. China)—for 30 minutes in staining buffer,
followed by secondary antibody—dylight 488 conjugated
donkey anti-rabbit IgG (Bethyl) and dylight 594 conju-
gated donkey anti-sheep IgG (Bethyl)—incubation forents
E1 (100 nM), CHIR99021 (3 μM)
E1 (100 nM), FGF4 (20 ng/ml), HGF (150 ng/ml)
GF (50 ng/ml), EGF (20 ng/ml), OsM (30 ng/ml), Dex (2 × 10−5 M), ITS (1×)
HGF hepatocyte growth factor, ITS insulin–transferrin–selenium, OsM
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ometer (BD Biosciences).
For detecting of asialoglycoprotein receptor (ASGPR),
5 × 105 iHeps (in 100 μl PBS) were incubated with
monoclonal antibodies (anti-ASGPR1-PE; Santa Cruz,
Chengdu, Sichuan, P.R. China) and incubated in the
dark at 2–8 °C for 30 minutes. After washing twice with
PBS, cells were resuspended in 300 μl PBS and analyzed
by the Calibur flow cytometer (BD Biosciences).
Immunofluorescence
For intracellular staining of ALB and AAT, the cells were
fixed with 4 % paraformaldehyde for 15 minutes at room
temperature and then incubated with PBS containing
0.2 % Triton X-100 (Sigma) for 15 minutes. Cells were
then washed three times with PBS. After being blocked by
3 % bovine serum albumin (BSA) in PBS for 60 minutes at
room temperature, cells were incubated with primary anti-
bodies at 4 °C overnight, washed three times with PBS, and
then incubated with appropriate fluorescence-conjugated
secondary antibody for 60 minutes at 37 °C in the dark.
Nuclei were stained with 4',6-diamidino-2-phenylindole
(DAPI; Sigma). Primary and secondary antibodies were di-
luted in PBS containing 3 % BSA. Antibodies used for im-
munofluorescence are as follows: sheep anti-ALB (1:500;
Bethyl), rabbit anti-AAT (1:1; Abcam, Chengdu, Sichuan,
P.R. China), rabbit anti-hepatocyte nuclear factor alpha-4
(anti-HNF4α, 1:50; Santa Cruz), rabbit anti-Ki67 (1:100;
Santa Cruz), dylight 488 conjugated donkey anti-rabbit IgG
(1:200; Bethyl), dylight 594 conjugated donkey anti-sheep
IgG (1:200; Bethyl), and Alexa Fluor 594 conjugated goat
anti-rabbit IgG (1:100; ZSBG-BIO, Chengdu, Sichuan, P.R.
China).
Real-time quantitative PCR
Total RNA was isolated from ADSCs, iHeps, and pri-
mary rat hepatocytes (rHeps) using the Trizol Reagent
(Sigma). Additional file 1 shows the sequences of both
forward and reverse primers in more detail. In parallel,
we analyzed the mRNA concentration of the rat
housekeeping GAPDH as an internal control for
normalization. The real-time monitoring of the PCR
reaction, the precise quantification of the products in
the exponential phase of the amplification, and the
melting curve analysis were performed with the Bio-
Rad CFX Manager software (Chengdu, Sichuan, P.R.
China), as recommended by the manufacturer.
Gene expression profile analysis
Total RNA was extracted and reverse transcript into
cDNA. Samples were then hybridized to the Affymetrix
Rat Gene 1.0ST (Chengdu, Sichuan, P.R. China) in ac-
cordance with the manufacturer’s instruction. Data were
normalized by Partek Genomics Suite 6.6 (Affymetrix,Beijing, P.R. China) in default analysis settings. Normal-
ized data were processed to the Kyoto Encyclopedia of
Genes and Genomes (KEGG, Chengdu, Sichuan, China)
for further pathway function analysis.
Periodic acid–Schiff staining, acetylated low-density
lipoprotein, and indocyanine green uptake assays, ALB
ELISA, and urea synthesis
iHeps were stained by Periodic acid–Schiff (PAS; Sigma)
following the manufacturer’s instructions. For the acety-
lated low-density lipoprotein (ac-LDL) uptake assay,
iHeps were incubated with 10 mg/ml DiI-labeled ac-
LDL (Life Technologies, Chengdu, Sichuan, China) at
37 °C for 1 hour and later washed three times with PBS.
For the indocyanine green (ICG; Sigma) uptake assay,
media of iHeps were changed with 1 mg/ml ICG and in-
cubated at 37 °C for 1 hour, followed by washing three
times with PBS. To determine ALB secretion in iHeps,
culture supernatants were collected daily and deter-
mined by the rat ALB ELISA kit (Bethyl) according to
the manufacturer’s instructions. Urea content was mea-
sured with diacetylmonoxime with a commercially avail-
able kit (StanBio Laboratory, Chengdu, Sichuan, China).
iHep transplantation to CCl4-induced acute fulminant liver
failure mice
NPG mice (6 weeks old, male; Beijing Vitalstar Biotech-
nology Co., Ltd, Chengdu, Sichuan, China) were injected
with CCl4 (Sigma) at a dose of 0.5 ml/kg body weight
through intraperitoneal injection. Eight hours after CCl4
treatment, ADSCs, iHeps, and rHeps (2 × 106 cells/ani-
mal) were injected into the spleens of the mice. Mean-
while, a sham operation group was used as negative
control. Blood and liver samples were collected after the
surviving animals were sacrificed. Blood samples were
used for blood biochemical analysis. Livers of recipient
mice were embedded in Tissue Freezing Medium (Leica,
Chengdu, Sichuan, China) and then frozen in liquid ni-
trogen. Cryostat sections (8 μm) were stained. All animal
experiments were in conformity with NIH guidelines
(NIH Pub. No. 85-23, revised 1996) and were approved
by the Animal Care and Use Committee of Sichuan
University, Chengdu, P.R. China.
In vivo tumor transplantation assay
Five BALB/c nude mice (6 weeks old, female; HFK Bio-
science, Beijing, China) were subcutaneously injected
with HepG2 or iHeps (1 × 106) on both sides of the back.
These mice were sacrificed 8 weeks after transplantation.
All animal experiments were in conformity with NIH
guidelines (NIH Pub. No. 85-23, revised 1996) and were
approved by the Animal Care and Use Committee of
Sichuan University.
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Characterization of ADSCs
The cultures were observed using an inverted light
microscope. Attachment of spindle-shaped cells to the
culture dish was observed after 1 day of culture
(Fig. 1a). Primary cultures reached 80–90 % conflu-
ence in approximately 4–5 days. During passaging,
the cell growth tended to accelerate and the morph-
ology of cells changed gradually. After three passages,
the cultures showed homogeneous fibroblastic morph-
ology (Fig. 1b). Flow cytometry analysis showed that
ADSCs possessed the surface marker profiles (CD29,
CD44, and CD90) typical for MSCs, and were negative for
hematopoietic marker (CD45) or endothelial marker
(CD31) indicating the absence of hematopoietic and endo-
thelial cells (Fig. 1c). When cultured in appropriate induc-
tion medium, ADSCs differentiated into adipocytes, which
were verified by Oil red O staining (Fig. 1d). They were
also able to differentiate into osteocytes, which were con-
firmed by Alizarin Red staining (Fig. 1d). Furthermore,
they could differentiate into chondrocytes, which were
identified by Alcian blue binding assay (Fig. 1d).Fig. 1 Characterization of rat ADSCs. a Primary ADSCs. b ADSCs in passage
morphology. c Expression of cell surface markers on ADSCs. ADSCs were p
negative for hematopoietic marker (CD45) or endothelial marker (CD31). d
into adipocytes, osteocytes, or chondrocytes. Scale bar: 250 μm (a, b,) 100Screening for induction protocols to generate iHeps from
ADSCs
For rapidly and highly efficiently generating mature
hepatocytes from ADSCs, we screened a series of hepa-
togenic induction strategies and finally confirmed a
three-step protocol which was described in Materials
and methods. In this protocol, ADSCs were allowed to
reach approximately 100 % confluence on collagen type
I-coated dishes, and were then treated with endodermal
induction medium on day 0 (Fig. 2a, I) in the presence
of IDE1 and CHIR99021. After 1 day, the cell morph-
ology turned from a long spindle shape into a short
spindle shape (Fig. 2a, II). Immunofluorescent staining
revealed that most of the cells were positive for the
definitive endoderm (DE) markers Sox17 and FoxA2
(Fig. 2b), indicating that the ADSCs efficiently differenti-
ated into DE during the endodermal induction step. Fol-
lowing the endodermal induction step, cells were treated
with the hepatogenic induction medium for 3 days,
which changed the cell morphology from a spindle shape
to a polygonal shape (Fig. 2a, III). Finally, the medium was
replaced with maturation medium which resulted in the3 with 90 % confluence. The cells showed homogeneous fibroblastic
ositive for mesenchymal stem markers (CD44, CD90, and CD29) and
Multiple differentiation potential of ADSCs. ADSCs could differentiate
μm (d)
Fig. 2 Screening for induction protocol to generate iHeps from ADSCs. a Sequential morphological changes from ADSCs to iHeps. I Cell
morphology before hepatic lineage induction. II Change of cell morphology with a short spindle shape after culture in endodermal induction
medium. III At day 4, the cell morphology had become polygonal in shape. IV Morphology of the mature iHeps. b Immunostaining revealed the
vast majority of induced cells were positive for the DE markers Sox17 and FoxA2 at day 1 (upper right, ADSCs). c Differentiation efficiency measured by
flow cytometry analysis marked by ALB, AAT, and ASGPR1. n = 3. d Gradual changes of hepatocytic gene expression in iHeps during hepatic lineage
induction. The expression levels of the indicated genes were analyzed by quantitative PCR. Data are normalized to iHeps at day 4. AAT
alpha-1-antitrypsin, ALB albumin, ASGPR asialoglycoprotein receptor, CK18 cytokeratin 18, d day, GJB1 gap junction protein beta-1, HNF4α
hepatocyte nuclear factor alpha-4, rHep primary rat hepatocyte, TAT tyrosine transaminase, TTR transthyretin, AFP alpha fetal protein. Scale
bar: 100 μm (a,) 50 μm (b). Data presented as mean ± standard deviation
Xu et al. Stem Cell Research & Therapy  (2015) 6:193 Page 5 of 10cell morphology changing into a typical cuboidal
shape of primary hepatocytes that had tight cell–cell
contact (Fig. 2a, IV). Flow cytometry analysis of these
hepatocyte-like cells (that is, iHeps) confirmed that
nearly 100 % of iHeps were ALB-positive, ~95 % were
AAT-positive, and ~91 % were ASGPR1-positive, indi-
cating that iHeps possess these typical markers of
mature hepatocytes (Fig. 2c). Furthermore, the ex-
pression of genes specific for mature hepatocytes (for
example, ALB, ASGPR1, and Transferrin) increased
gradually during iHep induction, while the expression
of alpha fetal protein (AFP) for immature hepatocytes
significantly upgraded in the hepatogenic induction
stage and descended to the level of rHeps in the
maturation step, suggesting that hepatic lineage differ-
entiation is a progressively coordinated process
(Fig. 2d). These results indicate that we successfully
obtain ADSC-derived mature hepatocytes using a new
procedure.iHeps possess the typical characteristics of mature
hepatocytes
Immunofluorescent staining showed that more than
90 % of iHeps expressed both ALB and AAT at day 9
(Fig. 3a), suggesting a highly-efficient hepatogenic differ-
entiation. To assess the metabolic activity of iHeps, we
quantified ALB production and urea synthesis. We
found that iHeps had a remarkable capability for secret-
ing the plasma protein ALB at a level close to rHeps at
day 9 (Fig. 3b). The cumulative urea amounts also grad-
ually increased in the iHep culture system during the
induction period (Fig. 3c). Genome-wide expression pro-
file analysis revealed that iHeps were clustered closely
with cultured rHeps (Fig. 3d). Furthermore, gene set en-
richment analysis showed that pathways enriched in
rHeps were significantly enriched in iHeps, including
those involved in glucose metabolism, lipid metabolism,
amino acid metabolism, and phase I and phase II detoxi-
fication (see Additional file 2). These data indicate that
Fig. 3 (See legend on next page.)
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Fig. 3 Characterization of iHeps in vitro. a Immunofluorescence analysis of ALB and AAT in iHeps. More than 90 % of iHeps efficiently expressed
both ALB and AAT at day 9. b Secretion of ALB increased during the hepatogenic induction period as measured by ELISA. c The cumulative urea
amounts gradually increased in the iHeps culture system during the hepatogenic induction period. d Gene expression profile analysis of ADSCs,
iHeps, and rHeps cells by cDNA microarray. Hierarchical clustering showed that iHeps were grouped together with rHeps. e Analysis of basic hepatic
function in iHeps, including PAS staining, ac-LDL, and ICG uptake. f mRNA levels of CYP genes were determined by quantitative PCR in iHeps and
rHeps before inducer treatment. Data normalized to the level of GAPDH. g mRNA levels of the induced CYP enzymes were measured by quantitative
PCR. CYP1A1and CYP1A2 was induced by 3-methylcholanthrene. CYP2A1 and CYP3A1 were induced by phenobarbital. CYP2E1 was induced by
acetone. Fold induction in iHeps and rHeps was normalized to levels in cells without inducer treatment, respectively. h CYP metabolic activity in iHeps.
CYP enzymes were induced in iHeps for 48 hours. Fresh rHeps were directly used as a positive control. The metabolic products of
phenacetin (acetaminophen, assay for CYP1A2 activities), coumarin (7-hydroxycoumarin, assay for CYP2A1 activities), and chlorzoxazone
(6-hydroxychlorzoxazone, assay for CYP2E1 activities) were determined by liquid chromatography–tandem mass spectrometry. Scale bar: 100 μm (a, e).
AAT alpha-1-antitrypsin, ac-LDL acetylated low-density lipoprotein, ADSC adipose-derived stem cell, ALB albumin, CYP cytochrome P, ICG indocyanine
green, iHep induced functional hepatocyte, PAS Periodic acid–Schiff, rHep primary rat hepatocyte, UD undetectable
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tional alterations. In accordance with the expression of
hepatic genes, iHeps displayed numerous hallmark func-
tions of mature hepatocytes, such as glycogen storage,
ac-LDL intake, and ICG uptake (Fig. 3e). The drug meta-
bolic capacity is one of the most important functions
that distinguish hepatocytes. CYP450 enzymes of hepa-
tocytes are the main enzymes accounting for drug me-
tabolism. Their activities and responses to specific
inducers are used to evaluate drug metabolism of hepa-
tocytes. We quantitatively confirmed the expression of
CYP enzymes in iHeps, CYP1A1, CYP1A2, CYP2A1,
CYP2C7, CYP2C12, CYP2E1, and CYP3A1. Results
showed that iHeps already expressed these genes at re-
markable levels without addition of chemical inducers
(Fig. 3f ). Furthermore, chemical inducers (3-methylcho-
lanthrene, phenobarbital, and acetone) could markedly
induce mRNA expression levels of CYP1A1, CYP1A2,
CYP2A1, CYP2E1, and CYP3A1, except for CYP2C7
and CYP2C12 (Fig. 3g). Importantly, in another assay for
CYP activities, iHeps displayed CYP enzyme-dependent
metabolism of phenacetin, coumarin, and chlorzoxazone
(Fig. 3h). These results offer the possibility of using
iHeps for toxicity screening during drug discovery.
iHeps improve CCl4-induced acute fulminant liver failure
To evaluate whether iHeps have sufficient hepatic func-
tions to support the liver in recovering from acute ful-
minant hepatitis, NPG mice (T, B, and natural killer
cell-depleted mice) were injected with CCl4 to trigger
acute fulminate hepatitis and animal death within
24 hours (Fig. 4a). ADSCs, iHeps, and rHeps were sep-
arately injected intrasplenically into NPG mice 8 hours
after CCl4 treatment (Fig. 4a). In groups of mice trans-
planted with ADSCs or sham operation, almost all
recipients died within 24 hours after CCl4 treatment
(one mouse in the sham operation group died at day 2;
Fig. 4b). rHep transplant significantly improved the
survival rate and extended the survival time of mice
with acute liver failure (Fig. 4b). Remarkably, upontransplant with iHeps, two of five mice completely re-
covered from CCl4-induced acute fulminant liver failure
(Fig. 4b) and showed normal serum alanine transamin-
ase (ALT) and glutamic-oxaloacetic transaminase
(AST) levels on day 7 after CCl4 treatment (Fig. 4c, d).
Rat ALB was also detected in the sera of mice trans-
planted with iHep cells (Fig. 4e). Histological analysis
revealed that iHeps significantly improved recovery
from CCl4-induced liver damage (Fig. 4f, g). Immuno-
fluorescence staining of rat ALB showed the repopula-
tion of iHeps in the liver parenchyma in the surviving
mice, and repopulated ALB-positive cells were posi-
tively stained by AAT, an antibody labeling both rat and
mouse hepatocytes (Fig. 4h). Remarkably, iHeps did not
fuse with mouse hepatocytes as determined by im-
munofluorescent staining using antibodies specifically
against rat ALB and mouse HNF4α (see Additional file
3). These results indicate that iHeps can populate the
liver and have a therapeutic effect in the treatment of
acute fulminant liver failure. Intriguingly, repopulated
iHeps were not proliferating as shown by Ki67 staining
8 weeks after transplantation (see Additional file 3). Fur-
thermore, we found that iHeps did not form tumors after
transplantation in immunodeficient mice (see Additional
file 4). Together, our data indicate that iHeps possess not-
able mature hepatocyte functions to support the liver in
recovering from acute fulminant failure.
Several studies have described the differentiation of
ADSCs into cells that display hepatocytic characteristics
[27–30]. However, those in vitro differentiation methods
are not applicable to practical use because about 1 month
is required to induce ADSCs into cells with hepatic
functions. Applications in the current study require a
special approach, such as shortening as much as pos-
sible, including cultivation and direct hepatic fate. In this
work, we presented a protocol which allowed ADSCs to
differentiate into functional hepatocytes in a short time.
Nine days is sufficient to obtain cells, which shows
hepatocyte-specific morphology, expression profiles, and
functions. To our knowledge, this is the first time such a
Fig. 4 Therapeutic effects of iHeps on acute liver failure. a Schematic diagram of iHep transplantation into the livers of NPG mice. NPG mice were injected with
carbon tetrachloride (CCl4) to trigger fulminant hepatitis, which led to acute liver failure and death within 24 hours in all mice. Eight hours after CCl4 treatment,
ADSCs, iHeps, and rHeps (2 × 106 cells/animal) were injected into the spleens of the mice. b Kaplan–Meier survival curve of NPG mice with acute liver failure
that did not receive cells (sham operation) or received 2× 106 ADSCs, iHeps, and rHeps. Almost all mice died in groups transplanted with ADSCs or sham
operation (one mouse in the sham operation group died at day 2), two of five recipient mice survived after transplantation with iHeps, and three of five mice
receiving rHep transplantation survived. Kaplan–Meier survival curve depicted. c, d Serum levels of ALT (c) and AST (d) in CCL4-treated mice before (day 0) and
after (day 7) transplantation of iHeps or rHeps. e Rat ALB levels were determined by ELISA in the sera of surviving NPG mice. f, g Livers in CCl4-treated mice
before (day 0) and after iHep transplantation (day 7). Macroscopic images of freshly isolated livers (f) and hematoxylin and eosin staining of liver sections (g).
Note CCl4-induced hepatitis and hemorrhage in the liver at day 0 (f), arrows in (g). The liver already recovered from CCl4-induced damage at day 7. h
Expression of ALB and AAT in engrafted iHeps revealed by immunofluorescence. The ALB antibody is rat specific and the AAT antibody reacts with both rat
and mouse. Data presented as mean± standard deviation. Scale bar: 5 mm (f), 100 μm(g, h). AAT alpha-1-antitrypsin, ADSC adipose-derived stem cell, ALB albu-
min, ALT alanine transaminase, AST glutamic-oxaloacetic transaminase, iHep induced functional hepatocyte, PAS Periodic acid–Schiff, rHep primary rat hepatocyte
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sented. In this protocol, ADSCs are first exposed to a
high level of transforming growth factor beta (TGF-β)/
activin/nodal (IDE1) and Wnt (CHIR99021) signaling in
a manner that is designed to mimic events during em-
bryonic development in order to allow DE formation
[31]. IDE1 is a small molecule compound and could in-
duce DE differentiation up to 80 % of mouse embryonic
stem cells (mESCs) (or 50 % of human embryonic stem
cells (hESCs)) in the absence of activin A (a typically
used DE inducer) [32, 33]. Similar to activin A, IDE1 in-
duces Smad2 phosphorylation in mESCs, while their tar-
gets remain unknown. In our study, a combination of
IDE1 and CHIR99021 (a specific chemical inhibitor of
GSK3) was able to efficiently drive ADSCs in a definitive
commitment to endoderm formation. Compared with
cells cultured in media without CHIR99021 (data not
shown), we found that the presence of CHIR99021
might have a synergistic effect with IDE1 and was able
to efficiently induce a rapid increase in the expression of
the DE markers Sox17 and FoxA2. The cell morphology
of ADSCs also quickly changes into a short spindle
shape within 1 day. This enables ADSCs to differentiate
into hepatocytes quickly and efficiently. Unlike the re-
cent studies [34–36], our data showed that more than
90 % of iHeps efficiently expressed both ALB and AAT
and secreted the plasma protein ALB at a level close to
primary rHeps after 9 days of induction. Furthermore,
iHeps possessed remarkable CYP enzyme activity which
was associated with drug metabolism. Additionally,
transplanted iHeps could repopulate livers of NPG mice
with acute fulminant liver failure and restore the liver
function. Taken together, our study provides a simple,
rapid, and high-efficiency protocol for the generation of
ADSC-derived iHeps suitable for cell-based therapy, as
well as an in vitro drug screening model.Conclusion
In summary, our study outlines rapid generation of ma-
ture functional hepatocyte cells from ADSCs by an effi-
cient three-step induction protocol. Furthermore, we have
shown therapeutic effects of these cells on CCl4-induced
acute fulminant liver failure. This work could contribute
to the development of alternative strategies to obtain non-
hepatic cell-derived mature hepatocytes with potential for
biomedical and pharmaceutical applications.Additional files
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